Skip to main content
S&P 5007,801.73-0.22%DOW51,228.03-0.57%NASDAQ27,510.29-0.32%BTC$83,299.00-2.85%ETH$2,557.22-5.24%GOLD$4,140.10-1.12%OIL$88.26-1.32%
Smart Investors Daily
SID Premium
RN

NASDAQ · RNXT

RenovoRx, Inc.

Healthcare · Biotechnology

$1.39

Up-$0.00 (+0.00%)

Updated Oct 7, 2026, 6:21 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
36.39M
P/E ratio
-3.41
Dividend yield
0.00%
52-week range
$0.77 – $2.59
Volume
621.68K
Avg. volume
506.07K

Price performance · RNXT

RNXT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RNXT closed at $1.39 after 21 trading sessions, down 36.82% for the selected period.

Last close
$1.39
Period change
-36.82%
Period low
$1.39
Period high
$2.20
Daily close
View OHLC price history
RNXT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.51$1.57$1.37$1.39621.68K
Oct 5, 2026$1.58$1.61$1.43$1.47618.03K
Oct 2, 2026$1.57$1.61$1.55$1.58269.37K
Oct 1, 2026$1.57$1.59$1.5001$1.55404.03K
Sep 30, 2026$1.57$1.64$1.54$1.56397.96K
Sep 29, 2026$1.57$1.59$1.51$1.57370.92K
Sep 28, 2026$1.65$1.65$1.50$1.55877K
Sep 25, 2026$1.69$1.725$1.6454$1.66490.85K
Sep 24, 2026$1.61$1.70$1.53$1.68630.07K
Sep 23, 2026$1.70$1.7999$1.60$1.63765.01K
Sep 22, 2026$1.70$1.73$1.67$1.70383.95K
Sep 21, 2026$1.69$1.74$1.6301$1.67482.55K
Sep 18, 2026$1.74$1.75$1.67$1.69566.88K
Sep 17, 2026$1.60$1.77$1.58$1.73636.08K
Sep 16, 2026$1.73$1.73$1.55$1.551.04M
Sep 15, 2026$1.692$1.73$1.60$1.721.03M
Sep 14, 2026$1.75$1.85$1.66$1.69579.67K
Sep 11, 2026$1.77$1.8199$1.67$1.761.17M
Sep 10, 2026$1.97$1.99$1.71$1.771.64M
Sep 9, 2026$2.15$2.30$1.935$1.9951.73M
Sep 8, 2026$2.31$2.345$2.1509$2.201.21M

Latest RNXT news

The latest Smart Investors Daily articles mentioning RNXT.

Stock researchCompany · Overview

RNXT research

Overview

Company profile and research snapshot.

Company profile

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
RNXT recent ratings
DateFirmRatingTarget
Aug 28, 2026Ascendiant CapitalBuy—
Jun 1, 2026Ascendiant CapitalBuy—
Apr 9, 2026Ascendiant CapitalBuy—
Apr 8, 2026HC Wainwright & Co.Buy—
Feb 17, 2026Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPCMOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case series i

Yahoo · Sep 2, 2026

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York P

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By